Zimmer Biomet Holdings (ZBH) Cost of Revenue (2009 - 2026)

Zimmer Biomet Holdings' Cost of Revenue history runs 18 years deep, the most recent figure standing at $576.2 million for Q1 2026.

• In Q1 2026, Cost of Revenue rose 4.8% year-over-year to $576.2 million; the TTM figure through Mar 2026 stood at $2.5 billion (up 13.07% YoY), while the FY2025 annual figure was $2.5 billion, up 13.81% from the prior year.
• Cost of Revenue was $576.2 million for Q1 2026 at Zimmer Biomet Holdings, down from $792.4 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $792.4 million in Q4 2025 to a low of $488.2 million in Q3 2022.
• Historically, Cost of Revenue has averaged $550.8 million across 5 years, with a median of $538.6 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue declined 3.02% in 2022, then surged 35.06% in 2025.
• A 5-year view of Cost of Revenue shows it stood at $520.3 million in 2022, then rose by 3.56% to $538.8 million in 2023, then climbed by 8.89% to $586.7 million in 2024, then soared by 35.06% to $792.4 million in 2025, then dropped by 27.28% to $576.2 million in 2026.
• The last three Cost of Revenue figures came in at $576.2 million (Q1 2026), $792.4 million (Q4 2025), and $559.3 million (Q3 2025), per Business Quant data.